Background -Gamma scintigraphy was employed to assess the deposition of aerosols emitted from a pressurised metered dose inhaler (MDI) contained in a microprocessor controlled device (SmartMist), a system which analyses an inspiratory flow profile and automatically actuates the MDI when predefined conditions of flow rate and cumulative inspired volume coincide. Methods -Micronised salbutamol particles contained in a commercial MDI (Ventolin) were labelled with 99m-technetium using a method validated by the determination of (1) aerosol size characteristics ofthe drug and radiotracer following actuation into an eight stage cascade impactor and (2) shot potencies ofthese non-volatile components as a function of actuation number. Using nine healthy volunteers in a randomised factorial interaction design the effect of inspiratory flow rate (slow, 30 1min; medium, 90 Vmin; fast, 270 /min) combined with cumulative inspired volume (early, 300 ml; late, 3000 ml) was determined on total and regional aerosol lung deposition using the technique of gamma scintigraphy. Results -The SmartMist firing at the mediumlearly setting (medium flow and early in the cumulative inspired volume) resulted in the highest lung deposition at 18-6 (1.42)%. The slow/early setting gave the second highest deposition at 14a1 (2.06)% with the fastllate setting resulting in the lowest (7.6 (1-15)%). Peripheral lung deposition obtained for the mediumlearly (9.1 (0.9)%) and slowlearly (7.5 (1.06)%) settings were equivalent but higher than those obtained with the other treatments. This reflected the lower total lung deposition at these other settings as no difference in regional deposition, expressed as a volume corrected central zone:peripheral zone ratio, was apparent for all modes of inhalation studied. Conclusions -The SmartMist device allowed reproducible actuation of an MDI at a preprogrammed point during inspiration. The extent ofaerosol deposition in the lung is affected by a change in firing point and is promoted by an inhaled flow rate of up to 90 1/min -that is, the slow and medium setting used in these studies. (Thorax 1995;50:639-644) 
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There is a growing awareness that optimising the extent of lung deposition (dose) and regional distribution of an inhaled drug could improve its therapeutic efficacy. This has obvious relevance for locally acting drugs such as aerosolised bronchodilators and corticosteroids. In addition, optimised delivery 
'Data calculated by expressing total inspired volumes as percentages of each individual's FVC, measured before aerosol administration. 640 group.bmj.com on June 20, 2017 -Published by http://thorax.bmj.com/ Downloaded from (100 seconds) were recorded using a gamma camera (GE Maxicamera 400A) fitted with a high resolution, low energy, parallel hole collimator and coupled to a SUN SPARC station IPX computer operating with commercial software (MAPS 10000; Link Medical Systems, Bourne End, UK). A complete record of each subject's inspiratory flow before, during, and after dosing was downloaded in real time from the SmartMist device to a personal computer running software developed for this purpose.
On a single occasion before the randomised study each volunteer received an 81im-krypton ventilation scan (anterior and posterior images) by tidal breathing`lmKr gas from a generator (Regional Radioisotope Centre, Dudley Road Hospital, Birmingham, UK) via a mouthpiece until views containing 200 000 counts were accumulated (100-200 seconds) by the gamma camera fitted with a medium energy collimator. A region of interest was drawn around the 20% contour of the geometric mean ventilation image to delineate the lung margin of each volunteer. This was superimposed on the anterior and reflected posterior deposition images, and a second region of interest drawn around an area equivalent to the peripheral lung using an established method. 8 The ratio between aerosol counts in the central and peripheral zones (C/P) was normalised with respect to regional lung volume by division ofthis value by a C/P ratio obtained from the corresponding geometric mean ventilation image. The resultant parameter is the regional aerosol distribution per unit volume, specific C/P (sC/P).
Regions of interest were also drawn to encompass radioactivity located in the stomach and mediastinum with a further area selected to represent background radiation. After back- ground correction the geometric mean counts in those areas of interest were calculated from the appropriate pair of anterior and posterior counts. Background correct mouth and pharyngeal counts were determined from the lateral views, while the radioactivity remaining in the actuator or deposited on the filter was determined by placing these items directly on the collimator ofthe gamma camera for a 30 second acquisition. The relative distribution of radioactivity in each of the areas of interest was calculated after further correction of counts in the anatomical regions for attenuation. For the lungs and stomach/mediastinum this was determined by measuring transmittance of radioactivity from a 99mTc flood source through the thorax of each volunteer, and comparison with a calibration curve of transmittance through acrylic polymer (Perspex) shields (1-25 cm thickness) to yield an "equivalent Perspex thickness". The reciprocal of transmittance through half this thickness of Perspex gave a value for attenuation of activity in each region. Attenuation in the mouth and pharynx was calculated from the anatomical dimensions of these structures.
STATISTICAL ANALYSIS
Comparisons between groups were made using two way ANOVA using a 5% level for type I errors. Where ANOVA indicated significant differences and more than two groups were involved in the experiment, Duncan's new multiple range test was used to identify significant differences between specific groups. A p value of less than 0 05 was considered significant. fig 3. In rare cases the actual firing point deviated from a the programmed ranges for inspiratory flow or cumulative inspired volume. These were always minor and occurred for: (1) firing flow for one actuation programmed to fire at the slow/early setting (47 1/min compared with 45 1/min) and one at the medium/early setting (117 1/min compared with 112 I/min); and (2) firing volume for a single fast/early setting (472 ml compared with 420 ml). For all programmed modes of aerosol actuation, however, the mean firing values for inspiratory flow and cumulative inspired volume were within the set ranges ( tings. The medium/early setting (firing at (1) (2) (3) (4) (5) (6) medium flow and early in the cumulative in- Autohaler) .' Use of the SmartMist device may have advantages over these other systems in that it controls the firing event in terms of the inspiratory flow and cumulative inhaled volume; both these factors were shown to have an effect on lung deposition. Conventional breath actuated systems merely restrict aerosol actuation until the patient commences inspiration -that is, there is no precise control over the flow and volume at which actuation occurs. Spacers optimise aerosol delivery by providing a chamber for modifying the size and velocity characteristics of the inhaled aerosol cloud. Consequently, they are bulky compared with a standard MDI or one loaded into a SmartMist device.
One unexpected finding was the small but significant improvement in lung deposition which occurred after firing the MDI at a medium inspiratory flow and early in the cumulative inspired volume compared with firing at a slow/early inhalation point. Based on earlier gamma scintigraphic evidence, the optimum inhalation mode for use with MDIs is one involving a slow inhalation (about 301/ min) and it is generally regarded that an inspiratory flow rate approaching 100 /min is too fast.'2 The reason for the conflicting data in this study is not known precisely, although it may be due to the fact that these current investigations were carried out in healthy volunteers rather than in patients with obstructive airways disease. Previously, however, no difference in total or regional deposition of pressurised aerosols has been found between normal and chronic bronchitic subjects.'8 Another possible explanation could be related to differences in the luminal dimension of the airways as a function of resistance to inspiration. For example, the airways may well be inflated to differing extents when slower rates of inhalation (for example, 30 /min) are achieved through a device offering negligible resistance to flow compared with one offering a significant resistance to inspiration.
One further reason may be explained with reference to table 1 where it is evident that, as the set firing flow is increased, the overall mean flow becomes significantly lower than the actual firing flow; this latter parameter significantly correlates with the observed maximum flow. From this observation it may be hypothesised that inhaled flow rates averaged over the entire inspiratory manoeuvre (that may take 5 seconds or more to complete for a slow inhalation) may not be a valid indicator of the flow rate at the precise point of aerosol actuation or during the period when the aerosol initially penetrates into the lung. In other words, a measured overall mean flow of 100 1/min may occur in a situation where the MDI is actually fired at a significantly higher flow rate. This would be especially true if the administration device did not include a restrictor to constrain the inhaled flow.
It has recently been shown'6 that the large airway response to salbutamol emitted from an MDI connected to a large volume spacer device is improved when adopting a faster (57 I/min) rather than a slower (25 1/min) inspiratory manoeuvre, a finding supported by a greater central deposition of the inhaled dose at the higher flow rate. Significant changes in regional lung deposition have also been reported for other MDIs inhaled at different flow rates. '4 While there were differences in the extent of peripheral and central lung deposition for the various firing points used in this study, these simply correlated with total lung deposition; no firing point dependence was demonstrated for sC/P.
In conclusion, the SmartMist device allowed reproducible actuation of an MDI at a preprogrammed point during inspiration. The extent of aerosol deposition in the lung was affected by a change in firing point and promoted by an inhaled flow rate of up to 901/ min -that is, the slow and medium setting used in these studies. In the healthy volunteers used in this study, the optimum conditions for aerosol lung deposition was an inhalation flow rate set between 68 and 112 1/min coincident with a firing point early during inspiration. The data suggest the importance of further investigations with this device in patients with obstructive lung disease. One ofthe advantages, however, of using the microprocessor controlled device is that aerosol administration becomes more controlled, a prerequisite for investigating the lung as a route of delivery of systemically active drugs. Under these circumstances the firing conditions described above could be used to improve the dose to lung and hence the bioavailable fraction of the inhaled drug.
